Hemab Therapeutics Advances Novel Therapies for Coagulation Disorders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 26 2026
0mins
Source: Yahoo Finance
- HMB-002 Clinical Validation: The first-in-human data for HMB-002 demonstrate significant elevation of Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels through subcutaneous dosing, with multiple dose assessments underway, potentially offering a new prophylactic treatment paradigm for Von Willebrand Disease (VWD).
- New Drug HMB-003 Launch: Hemab announced HMB-003 as a potent peptide plasmin inhibitor, with first-in-human studies planned for the second half of 2026, aimed at reducing bleeding across various conditions, showcasing broad clinical application potential.
- Sutacimig Long-term Efficacy: Long-term extension data for Sutacimig in Glanzmann Thrombasthenia (GT) show sustained reductions in annualized treated bleeding rate (ATBR), with FDA granting Breakthrough Therapy designation, and Phase 3 initiation expected in the second half of 2026.
- International Conference Showcase: Hemab will present nine research findings at the 2026 International Society on Thrombosis and Haemostasis (ISTH) Congress, reflecting its progress in addressing critical gaps in the treatment of various coagulation disorders and emphasizing the company's commitment to meeting unmet medical needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COAG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COAG
Wall Street analysts forecast COAG stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 29.970
Low
Averages
High
Current: 29.970
Low
Averages
High
About COAG
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. It designs its assets to address critical gaps in the treatment of coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Its second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor (VWF), and Factor VIII, a blood coagulation protein. It is also advancing multiple preclinical and discovery-stage assets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hemab Therapeutics Advances Novel Therapies for Coagulation Disorders
- HMB-002 Clinical Validation: The first-in-human data for HMB-002 demonstrate significant elevation of Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels through subcutaneous dosing, with multiple dose assessments underway, potentially offering a new prophylactic treatment paradigm for Von Willebrand Disease (VWD).
- New Drug HMB-003 Launch: Hemab announced HMB-003 as a potent peptide plasmin inhibitor, with first-in-human studies planned for the second half of 2026, aimed at reducing bleeding across various conditions, showcasing broad clinical application potential.
- Sutacimig Long-term Efficacy: Long-term extension data for Sutacimig in Glanzmann Thrombasthenia (GT) show sustained reductions in annualized treated bleeding rate (ATBR), with FDA granting Breakthrough Therapy designation, and Phase 3 initiation expected in the second half of 2026.
- International Conference Showcase: Hemab will present nine research findings at the 2026 International Society on Thrombosis and Haemostasis (ISTH) Congress, reflecting its progress in addressing critical gaps in the treatment of various coagulation disorders and emphasizing the company's commitment to meeting unmet medical needs.
See More
Hemab Therapeutics Poised for Growth Post-IPO Amid Rare Disorder Treatment Progress
- Strong IPO Performance: Hemab Therapeutics went public on May 4 at $18 per share, doubling on its first day to a high of $36.61, indicating strong market confidence in its potential to treat rare diseases.
- Optimistic Analyst Ratings: Goldman Sachs initiated coverage with a Buy rating and a $36 price target, implying a 39% upside from Friday's close, reflecting high expectations for its drug sutacimig targeting rare bleeding disorders.
- Significant Market Potential: Sutacimig aims to treat Glanzmann's thrombasthenia and Factor VII deficiency, with only about 1,000 patients in the U.S., but up to five times that number in Gulf Cooperation Council countries, showcasing substantial market capture potential.
- Positive Clinical Trial Results: Early-phase trials of sutacimig demonstrated annualized bleeding rate reductions across all dosing regimens, while Hemab is also developing HMB-002 for the more common Von Willebrand disease, further enhancing its market outlook.
See More
Latest Wall Street Rating Updates
- Vipshop Rating Upgrade: UBS upgraded Vipshop (VIPS) from Neutral to Buy, indicating that despite near-term growth pressures, the company's earnings quality and shareholder returns are more attractive, showcasing resilience in a competitive e-commerce landscape.
- Seaport Therapeutics Initiation: JPMorgan initiated coverage on Seaport Therapeutics (SPTX) with an Overweight rating and a price target of $42 for December 2027, reflecting bullish sentiment and highlighting the company's potential for growth in the biotech sector.
- Apple Price Target Increase: Bank of America raised its price target on Apple (AAPL) from $330 to $380, emphasizing significant opportunities in agentic AI, while reiterating a Buy rating, which underscores confidence in the company's future growth trajectory.
- Dave Inc. Initial Rating: UBS initiated coverage on Dave Inc. with a Buy rating and a price target of $300, suggesting that the market underestimates the durability of its high-velocity credit model and earnings growth trajectory, indicating strong future potential.
See More
Hemab Therapeutics Q1 Financial Overview
- Financial Performance: Hemab Therapeutics reported a Q1 GAAP EPS of -$23.98, indicating significant challenges in profitability that could undermine investor confidence and future financing capabilities.
- Cash Position: As of March 31, 2026, Hemab's cash, cash equivalents, and marketable securities totaled $163.5 million, down from $185.5 million as of December 31, 2025, suggesting a need for more prudent cash management to sustain operations.
- IPO Efforts: Hemab Therapeutics is pursuing an IPO based on positive trial results, aiming to enhance liquidity and support future R&D projects, although the current financial situation may negatively impact market reception.
- Market Dynamics: The upsized IPOs of Hemab and Seaport are expected to raise $550 million, reflecting market confidence in clinical-stage biotech companies and potentially providing Hemab with essential funding to address its financial challenges.
See More
Odyssey Therapeutics Raises $279 Million in Upsized IPO
- Upsized Fundraising: Odyssey Therapeutics successfully raised $279 million in its U.S. IPO by selling 15.5 million shares at $18 each, exceeding its expected range of $16 to $18, indicating strong market demand for biopharmaceutical companies.
- Market Recovery Context: The U.S. biotech IPO market has seen a revival in 2026, driven by policy shifts under President Trump and significant FDA reforms, prompting several biotech firms, including Seaport Therapeutics and Kailera Therapeutics, to go public recently.
- Research Focus: Odyssey is dedicated to developing treatments for autoimmune and inflammatory diseases, with its drug OD-001 currently in mid-stage trials for ulcerative colitis, highlighting its potential in the therapeutic landscape.
- Planned Use of Proceeds: The company intends to allocate the proceeds primarily for the clinical development of OD-001 and for general corporate purposes, further advancing its research efforts and laying the groundwork for future market expansion.
See More
Hemab Therapeutics Successfully IPOs, Raising $346.7 Million
- IPO Financing Details: Hemab Therapeutics began trading on the Nasdaq Global Select Market on May 1, 2026, successfully completing an upsized IPO that raised approximately $346.7 million by issuing 19,262,500 shares at $18.00 each, reflecting the full exercise of underwriters' option for an additional 2,512,500 shares.
- Underwriting Team: The IPO was managed by Goldman Sachs, Jefferies, and Evercore ISI as joint book-running managers, with Wedbush PacGrow serving as lead manager, indicating strong market confidence and support for Hemab.
- Pipeline Development: Hemab is focused on developing next-generation therapies for serious inherited bleeding and thrombotic disorders, with Sutacimigis and HMB-002 both in Phase 2 clinical development, aimed at addressing significant unmet needs across various rare coagulation diseases.
- Stock Price Fluctuation: COAG's stock has traded between $24.94 and $36.61 since its IPO, closing at $25.34 on Monday, down 25.47% from the offering price, reflecting cautious market sentiment regarding its future prospects.
See More
Hemab Therapeutics Advances Novel Therapies for Coagulation Disorders
- HMB-002 Clinical Validation: The first-in-human data for HMB-002 demonstrate significant elevation of Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels through subcutaneous dosing, with multiple dose assessments underway, potentially offering a new prophylactic treatment paradigm for Von Willebrand Disease (VWD).
- New Drug HMB-003 Launch: Hemab announced HMB-003 as a potent peptide plasmin inhibitor, with first-in-human studies planned for the second half of 2026, aimed at reducing bleeding across various conditions, showcasing broad clinical application potential.
- Sutacimig Long-term Efficacy: Long-term extension data for Sutacimig in Glanzmann Thrombasthenia (GT) show sustained reductions in annualized treated bleeding rate (ATBR), with FDA granting Breakthrough Therapy designation, and Phase 3 initiation expected in the second half of 2026.
- International Conference Showcase: Hemab will present nine research findings at the 2026 International Society on Thrombosis and Haemostasis (ISTH) Congress, reflecting its progress in addressing critical gaps in the treatment of various coagulation disorders and emphasizing the company's commitment to meeting unmet medical needs.
See More
Hemab Therapeutics Poised for Growth Post-IPO Amid Rare Disorder Treatment Progress
- Strong IPO Performance: Hemab Therapeutics went public on May 4 at $18 per share, doubling on its first day to a high of $36.61, indicating strong market confidence in its potential to treat rare diseases.
- Optimistic Analyst Ratings: Goldman Sachs initiated coverage with a Buy rating and a $36 price target, implying a 39% upside from Friday's close, reflecting high expectations for its drug sutacimig targeting rare bleeding disorders.
- Significant Market Potential: Sutacimig aims to treat Glanzmann's thrombasthenia and Factor VII deficiency, with only about 1,000 patients in the U.S., but up to five times that number in Gulf Cooperation Council countries, showcasing substantial market capture potential.
- Positive Clinical Trial Results: Early-phase trials of sutacimig demonstrated annualized bleeding rate reductions across all dosing regimens, while Hemab is also developing HMB-002 for the more common Von Willebrand disease, further enhancing its market outlook.
See More
Latest Wall Street Rating Updates
- Vipshop Rating Upgrade: UBS upgraded Vipshop (VIPS) from Neutral to Buy, indicating that despite near-term growth pressures, the company's earnings quality and shareholder returns are more attractive, showcasing resilience in a competitive e-commerce landscape.
- Seaport Therapeutics Initiation: JPMorgan initiated coverage on Seaport Therapeutics (SPTX) with an Overweight rating and a price target of $42 for December 2027, reflecting bullish sentiment and highlighting the company's potential for growth in the biotech sector.
- Apple Price Target Increase: Bank of America raised its price target on Apple (AAPL) from $330 to $380, emphasizing significant opportunities in agentic AI, while reiterating a Buy rating, which underscores confidence in the company's future growth trajectory.
- Dave Inc. Initial Rating: UBS initiated coverage on Dave Inc. with a Buy rating and a price target of $300, suggesting that the market underestimates the durability of its high-velocity credit model and earnings growth trajectory, indicating strong future potential.
See More
Hemab Therapeutics Q1 Financial Overview
- Financial Performance: Hemab Therapeutics reported a Q1 GAAP EPS of -$23.98, indicating significant challenges in profitability that could undermine investor confidence and future financing capabilities.
- Cash Position: As of March 31, 2026, Hemab's cash, cash equivalents, and marketable securities totaled $163.5 million, down from $185.5 million as of December 31, 2025, suggesting a need for more prudent cash management to sustain operations.
- IPO Efforts: Hemab Therapeutics is pursuing an IPO based on positive trial results, aiming to enhance liquidity and support future R&D projects, although the current financial situation may negatively impact market reception.
- Market Dynamics: The upsized IPOs of Hemab and Seaport are expected to raise $550 million, reflecting market confidence in clinical-stage biotech companies and potentially providing Hemab with essential funding to address its financial challenges.
See More
Odyssey Therapeutics Raises $279 Million in Upsized IPO
- Upsized Fundraising: Odyssey Therapeutics successfully raised $279 million in its U.S. IPO by selling 15.5 million shares at $18 each, exceeding its expected range of $16 to $18, indicating strong market demand for biopharmaceutical companies.
- Market Recovery Context: The U.S. biotech IPO market has seen a revival in 2026, driven by policy shifts under President Trump and significant FDA reforms, prompting several biotech firms, including Seaport Therapeutics and Kailera Therapeutics, to go public recently.
- Research Focus: Odyssey is dedicated to developing treatments for autoimmune and inflammatory diseases, with its drug OD-001 currently in mid-stage trials for ulcerative colitis, highlighting its potential in the therapeutic landscape.
- Planned Use of Proceeds: The company intends to allocate the proceeds primarily for the clinical development of OD-001 and for general corporate purposes, further advancing its research efforts and laying the groundwork for future market expansion.
See More
Hemab Therapeutics Successfully IPOs, Raising $346.7 Million
- IPO Financing Details: Hemab Therapeutics began trading on the Nasdaq Global Select Market on May 1, 2026, successfully completing an upsized IPO that raised approximately $346.7 million by issuing 19,262,500 shares at $18.00 each, reflecting the full exercise of underwriters' option for an additional 2,512,500 shares.
- Underwriting Team: The IPO was managed by Goldman Sachs, Jefferies, and Evercore ISI as joint book-running managers, with Wedbush PacGrow serving as lead manager, indicating strong market confidence and support for Hemab.
- Pipeline Development: Hemab is focused on developing next-generation therapies for serious inherited bleeding and thrombotic disorders, with Sutacimigis and HMB-002 both in Phase 2 clinical development, aimed at addressing significant unmet needs across various rare coagulation diseases.
- Stock Price Fluctuation: COAG's stock has traded between $24.94 and $36.61 since its IPO, closing at $25.34 on Monday, down 25.47% from the offering price, reflecting cautious market sentiment regarding its future prospects.
See More
